Julia Karow

The €700 million project will pilot diagnostic genomic testing for cancer and rare diseases for at least five years, but private labs cannot participate.

In a trial of 23 Lynch syndrome patients, those who received the vaccine and developed neoantigen-specific T cells had a higher chance of remaining disease-free over 10 years.

More than 40 percent of patients in the Zero Childhood Cancer precision medicine program received a treatment recommendation based on their multiomic profiling results.

At the American College of Medical Genetics and Genomics annual meeting, NICHD Director Diana Bianchi reported that whole-body MRI was the best follow-up test to confirm or rule out cancer.

For just under $3,000, the company analyzes DNA from a child's saliva sample by whole-genome sequencing, screening for genetic variants associated with more than 300 diseases.

With reimbursement from public health insurance, the "model project" will run for at least five years and examine the utility of genomic sequencing for advanced cancer and rare disease patients.

At the International Conference on Newborn Sequencing (ICoNS) in London last week, a dozen projects from around the world presented their plans and progress.

The Singapore-based company plans to launch the epiHera test in August, following interim results from a clinical study with researchers at the Chinese University of Hong Kong.

Patients in Illumina's global iHope philanthropic clinical WGS program saw changes in their management regardless of whether they lived in wealthy or poor countries.

Overall, the organization remains skeptical of the clinical implementation of PRS testing, pointing to limitations of the tests and a lack of evidence for their clinical utility.